Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients

Publisher： Karger

E-ISSN： 1423-0232|91|5|283-288

ISSN： 0030-2414

Source： Oncology, Vol.91, Iss.5, 2016-08, pp. : 283-288

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI

By  

Oncology, Vol. 88, Iss. 3, 2014-11 ,pp. : 164-172

Karger

Access to resources Recommend Favorite

The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 224-230

Karger

Access to resources Recommend Favorite

Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 185-191

Karger

Access to resources Recommend Favorite

A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer

By  

Oncology, Vol. 88, Iss. 6, 2015-0 ,pp. : 353-359

Karger

Access to resources Recommend Favorite

Irinotecan in Second-Line Therapy of Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 4, 2000-05 ,pp. : 15-17

Karger

Access to resources Recommend Favorite